MONITORING AND EVALUATION FRAMEWORK FOR HBV AND HCV ELIMINATION

10 CORE INDICATORS: GLOBAL AND NATIONAL LEVELS

EPIDEMIC

C.1 Prevalence
- Chronic HBV infection
- Chronic HCV infection

C.2 Testing Infrastructure for HBV and HCV testing

SYSTEM

C.3 Vaccine coverage
- Timely HBV vaccine birth dose and other interventions to prevent mother-to-child transmission of HBV
- Third-dose HBV vaccine

C.4 Harm reduction
Needle–syringe distribution

C.5 Injection safety
Facility-level injection safety

C.6 People diagnosed
People living with HBV and/or HCV diagnosed

C.7 Treatment coverage/initiation
- Treatment coverage for HBV patients
- Treatment initiation for HCV patients

C.8 Treatment effectiveness
- Viral suppression for chronic HBV patients treated
- Cure for chronic HCV patients treated

C.9 Incidence
- Cumulated incidence of HBV infection in children 5 years of age
- Incidence of HCV infection

C.10 Attributable mortality HCC, cirrhosis
Deaths from liver diseases attributable to HBV and HCV infection

INPUTS

PREVENTION

C.11 Prevention campaigns
C.12 Education of health-care workers
C.13 Abstinence

OUTPUTS AND OUTCOMES

CASCADe OF CARE

Test
- Test

Treat
- Treat

Heal
- Heal

CONTEXT

Heal

Treat
- Treat

People diagnosed
People living with HBV and/or HCV diagnosed

Test
- Test

27 ADDITIONAL INDICATORS: NATIONAL OR LOCAL LEVELS

EXISTING INDICATORS

17

NEW HEPATITIS INDICATORS

10

A.1 Hepatitis D coinfection among people with HBV
A.2 Experience with discrimination
A.3 Availability of essential medicines and commodities
A.4 National system for viral hepatitis surveillance
A.5 HBV testing
A.6 HCV testing
A.7 HCV genotyping
A.8 HBV and HCV care coverage
A.9 Equitable access to hepatitis treatment
A.10 Documentation of treatment outcome

A.11 Estimated size of key populations (HIV)
A.12 Key populations discrimination (HIV)
A.13 Hepatitis coinfections among persons with HIV
A.14 Condom use in key populations (HIV)
A.15 National provision of a birth dose of HBV vaccine
A.16 HCV vaccination among health-care workers
A.17 Facility-level blood safety
A.18 Blood screening coverage
A.19 National policy for infection control programmes
A.20 Supply of needles–syringes

A.21 Procurement of reuse prevention devices
A.22 Reuse of injection equipment
A.23 Needle–syringe injuries among health-care workers
A.24 Opioid substitution therapy (OST) coverage
A.25 Retention in OST
A.26 Incidence of cancer, by cancer type
A.27 Alcohol consumption per capita (age 15+ years)

A: Additional indicators.

C: Core indicators.

HCC: Hepatocellular carcinoma.

2013 World Health Organization

Global Hepatitis Programme
Department of HIV/AIDS
http://www.who.int/hiv/topics/hepatitis/en/